The stock of Allergan plc Ordinary Shares (NYSE:AGN) is a huge mover today! About 1.63 million shares traded hands. Allergan plc Ordinary Shares (NYSE:AGN) has declined 21.34% since March 1, 2016 and is downtrending. It has underperformed by 30.59% the S&P500.
The move comes after 9 months positive chart setup for the $92.16 billion company. It was reported on Oct, 4 by Barchart.com. We have $369.50 PT which if reached, will make NYSE:AGN worth $52.53B more.
Analysts await Allergan plc Ordinary Shares (NYSE:AGN) to report earnings on November, 2. They expect $3.56 earnings per share, up 2.30% or $0.08 from last year’s $3.48 per share. AGN’s profit will be $1.39 billion for 16.53 P/E if the $3.56 EPS becomes a reality. After $3.35 actual earnings per share reported by Allergan plc Ordinary Shares for the previous quarter, Wall Street now forecasts 6.27% EPS growth.
Allergan plc Ordinary Shares (NYSE:AGN) Ratings Coverage
Out of 16 analysts covering Allergan Inc. (NYSE:AGN), 13 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 81% are positive. Allergan Inc. has been the topic of 40 analyst reports since July 29, 2015 according to StockzIntelligence Inc. On Wednesday, July 29 the stock rating was upgraded by TheStreet to “Buy”. Mizuho maintained the stock with “Neutral” rating in Friday, August 5 report. Deutsche Bank maintained the shares of AGN in a report on Friday, August 7 with “Buy” rating. The firm earned “Buy” rating on Friday, October 9 by Mizuho. The firm earned “Buy” rating on Tuesday, November 24 by Mizuho. The rating was maintained by RBC Capital Markets on Friday, August 7 with “Outperform”. The stock has “Buy” rating given by Deutsche Bank on Friday, August 7. JP Morgan reinitiated the stock with “Overweight” rating in Thursday, April 7 report. The stock of Allergan plc Ordinary Shares (NYSE:AGN) has “Neutral” rating given on Monday, April 18 by Piper Jaffray. The company was initiated on Friday, February 19 by Wells Fargo.
According to Zacks Investment Research, “Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment decreased to 0.46 in Q2 2016. Its down 0.29, from 0.75 in 2016Q1. The ratio worsened, as 11 funds sold all Allergan plc Ordinary Shares shares owned while 2 reduced positions. 3 funds bought stakes while 3 increased positions. They now own 58,328 shares or 8.83% less from 63,978 shares in 2016Q1.
Dowling Yahnke Lc reported 2,145 shares or 0.06% of all its holdings. Chartist Ca holds 0% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN) for 1,844 shares. Bartlett & Ltd reported 494 shares or 0.01% of all its holdings. Marshwinds Advisory Company has 0.1% invested in the company for 927 shares. Connors Investor Service Inc has invested 0.04% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN). Gemmer Asset Ltd Limited Liability Company owns 127 shares or 0.02% of their US portfolio. Frontier Investment Mngmt has 0.94% invested in the company for 32,758 shares. Mitchell Mcleod Pugh Williams last reported 0.83% of its portfolio in the stock. The Pennsylvania-based Armstrong Henry H Associates has invested 0.17% in Allergan plc Ordinary Shares (NYSE:AGN). Grassi Investment holds 0.22% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN) for 5,125 shares. Moreover, Research And Mngmt Commerce has 0% invested in Allergan plc Ordinary Shares (NYSE:AGN) for 33 shares. Mengis Capital Mgmt Inc has 1.27% invested in the company for 6,210 shares.
Another recent and important Allergan plc Ordinary Shares (NYSE:AGN) news was published by Investorplace.com which published an article titled: “Allergan plc Ordinary Shares: What Is AGN Getting for Its Billion Dollars?” on September 20, 2016.
AGN Company Profile
Allergan plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Firm is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company’s divisions are US Brands, US Medical Aesthetics and International Brands. The US Brands segment includes sales and expenses relating to branded products within the United States, including certain Botox therapies. The US Medical Aesthetics segment includes sales and expenses relating to aesthetics and dermatology products within the United States, including certain Botox therapies. The International Brands segment includes sales and expenses relating to products sold outside of the United States. The Firm has global rights to RST-001, a gene therapy approach for the potential treatment of retinitis pigmentosa (RP). The RST-001 optogenetic approach includes a photosensitivity gene, channelrhodopsin-2, to create new photosensors in retinal ganglion cells to restore vision in retinal degenerative conditions. The RST-001 is in Phase I/IIa clinical trials. It has global rights to AKN-083, a preclinical farnesoid X receptor (FXR) agonist for the treatment of non-alcoholic steatohepatitis (NASH).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.